PTC Therapeutics

hC Bioscience Announces Extension of Series A to $40 Million

Retrieved on: 
Friday, November 4, 2022
RNA transfection, Protein, Therapy, PTC Therapeutics, Disease, HC, GLOBE, Mutation, Patient, Genetic code, Cancer, Vaccine

hC Bioscience is creating engineered tRNAs with the power to overcome disease-causing issues in the genetic code as proteins are made.

Key Points: 
  • hC Bioscience is creating engineered tRNAs with the power to overcome disease-causing issues in the genetic code as proteins are made.
  • We are thrilled to announce our Series A extension of $16 million and welcome Seiji Miyahara, Taiho Ventures, and Benjamin Chen, Panacea Venture, to our board of directors, said Leslie Williams, co-founder, director and chief executive officer of hC Bioscience.
  • It further underscores investor confidence in the hC Bioscience team to continue to make progress toward bringing tRNA based therapeutics to the clinic.
  • hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting protein dysfunction.

Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 3, 2022
GLOBE, Investor, Mitochondrion, Adenosine triphosphate, PTC Therapeutics, Gene, Patient, ATP, Degenerative disease, NASDAQ, Pharmaceutical industry

IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the companys management team will participate at three upcoming healthcare conferences.

Key Points: 
  • IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the companys management team will participate at three upcoming healthcare conferences.
  • Date: November 29 December 1, 2022
    Links to the presentations will be posted on the Investors section of the Reneo Pharmaceuticals corporate website.
  • Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).
  • Our lead product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPAR).

Biotechnology Innovators Honored in 2022 BioTech Breakthrough Awards Program

Retrieved on: 
Thursday, November 3, 2022
Growth, Solution, Ology Bioservices, Waters Corporation, Program, PTC, Biotechnology, Industry, Leadership, Honeywell, PTC Therapeutics, Biorefinery, Degenerative disease, Sutro Biopharma, Therapy, Food science, Scientist.com (company), Fine chemical, Vaccine, Industrial design, Professional services, Genomics, Immunology

LOS ANGELES, Nov. 3, 2022 /PRNewswire-PRWeb/ -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced the results of the second annual BioTech Breakthrough Awards program. The winning BioTech Breakthrough selections for 2022 showcase life sciences and biotechnology companies that push ingenuity and exemplify the best in biotech solutions across the globe.

Key Points: 
  • LOS ANGELES, Nov. 3, 2022 /PRNewswire-PRWeb/ -- BioTech Breakthrough , a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced the results of the second annual BioTech Breakthrough Awards program.
  • The winning BioTech Breakthrough selections for 2022 showcase life sciences and biotechnology companies that push ingenuity and exemplify the best in biotech solutions across the globe.
  • The mission of the annual BioTech Breakthrough Awards program is to conduct the industry's most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today.
  • The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more.

Loulou Foundation announces First-Patient-In for CANDID observational study on CDKL5 Deficiency Disorder

Retrieved on: 
Monday, October 31, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Secondary research, Epilepsy, Alliance, Peripheral nervous system, View, Observational study, Genome, MRNS, Food, Neurodevelopmental disorder, Therapy, Research, Partnership, Biogen, PTC Therapeutics, Penn, Genetic disorder, Disability in Canada, Patient, Binary relation, Biology, Spasm, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BIIB, Foundation, CDKL5, UCB, Ultragenyx, RARE, University, National Clinical Assessment Service, Communication, Program, Neuron, Seizure, Life, Incidence, Frasier, Pharmaceutical industry, CDD, Medicine

The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that the first patient has been enrolled in the three-year observational study with CDD patients, the Clinical Assessment of NeuroDevelopmental measures In CDD (CANDID) study.

Key Points: 
  • The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that the first patient has been enrolled in the three-year observational study with CDD patients, the Clinical Assessment of NeuroDevelopmental measures In CDD (CANDID) study.
  • The CANDID study is directed by a novel consortium of seven biopharmaceutical industry partners, together with the Loulou Foundation , to enable the development of disease-modifying therapeutics for CDD.
  • The Loulou Foundation serves as the study coordinator, while the seven partners share the funding and governance of this study involving CDD clinical centers worldwide.
  • CDKL5 Deficiency Disorder (CDD) is a neurodevelopmental disorder caused by loss-of-function mutations in the CDKL5 gene, which encodes a kinase necessary for the proper function of neurons.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

Retrieved on: 
Sunday, October 30, 2022
PTC, NASDAQ, PTC Therapeutics, Company, GLOBE, Pomerantz, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Food, Therapy, Private investigator

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (PTC or the Company) (NASDAQ:PTCT).

Key Points: 
  • NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (PTC or the Company) (NASDAQ:PTCT).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

Retrieved on: 
Saturday, October 22, 2022
News, Pomerantz, Therapy, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PTC Therapeutics, Company, PTC, Food, GLOBE, Private investigator

NEW YORK, Oct. 22, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (PTC or the Company) (NASDAQ:PTCT).

Key Points: 
  • NEW YORK, Oct. 22, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (PTC or the Company) (NASDAQ:PTCT).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, October 13, 2022
LinkedIn, NASDAQ, Patient, Company, PTC Therapeutics, Therapy, Twitter, PTC, Pharmaceutical industry, Instagram, Facebook

SOUTH PLAINFIELD, N.J., Oct. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2022 financial results and provide an update on the company's business and outlook on Thursday, Oct. 27, at 4:30 p.m.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Oct. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2022 financial results and provide an update on the company's business and outlook on Thursday, Oct. 27, at 4:30 p.m.
  • To access the call by phone, please click here to register and you will be provided with dial-in details.
  • To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call.
  • The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .

PTC Therapeutics to Present Clinical and Real-World Evidence on Translarna™ at the Annual Congress of the World Muscle Society

Retrieved on: 
Tuesday, October 11, 2022
Lists of diseases, European Medicines Agency, LinkedIn, Muscle, Genetic code, Dystrophin, Therapy, Population, STRIDE, WMS, Muscle weakness, PTC Therapeutics, Patient, Twitter, Instagram, Program, Diaphragm, TREAT-NMD, PTC, Partnership, DMD, Duchenne muscular dystrophy, Company, European Economic Area, Registry, Death, Congress, Safety, Observational study, Committee, Heart, Windows Internal Database, Dentistry, Pharmaceutical industry, Duchenne, Facebook, Ataluren

SOUTH PLAINFIELD, N.J., Oct. 11, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that recent clinical trial and real-world evidence on the efficacy and safety of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) will be presented at the 27th International Annual Congress of the World Muscle Society (WMS) in Halifax, Nova Scotia, Canada.

Key Points: 
  • A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein.
  • Translarna, the tradename of ataluren, is licensed in the European
    Economic Area for the treatment of Duchenne in ambulatory patients aged 2 years and older.
  • Study 041 is the largest prospective trial conducted in Duchenne, with an Intent-to-Treat population of 359 boys with Duchenne.
  • It is the first patient data repository to provide real-world experience regarding the long-term use of Translarna in routine clinical practice.

Imre Names Neera Chaudhary as Next Chief Executive Officer

Retrieved on: 
Thursday, October 6, 2022
Health, AstraZeneca, Bausch & Lomb, GSK, Imre, Culture, Therapy, Growth, Amgen, PTC Therapeutics, LGBTQ, Airstream, RLH, Multimedia, Investment, Executive, Partnership, History, Neera, AOR, Marketing, Board, Data Analytics Acceleration Library, Director, Board of directors, DNA, View, Leadership, Management, Pharmaceutical industry, Public relations

NEW YORK, Oct. 6, 2022 /PRNewswire/ -- imre today announces the appointment of Neera Chaudhary as its next Chief Executive Officer. Based in New York City, Chaudhary joined the agency on September 21, and will report to the agency's Board of Directors. Dave Imre, the agency's founder, will take on the role of Executive Chairman and remains a member of the Board of Directors. 

Key Points: 
  • NEW YORK, Oct. 6, 2022 /PRNewswire/ -- imre today announces the appointment of Neera Chaudhary as its next Chief Executive Officer.
  • Dave Imre, the agency's founder, will take on the role of Executive Chairman and remains a member of the Board of Directors.
  • Most recently serving as North America President of Ketchum, Chaudhary will lead imre's next growth phase as a leading full-service AOR.
  • As Executive Chairman, my role will evolve to support Neera and the executive leadership team with culture and talent mentorship," added Imre.

BioNJ Announces the Launch of Its Health Equity in Clinical Trials Initiative

Retrieved on: 
Tuesday, September 27, 2022
Science, Volunteering, Safety, Gaps, Crash, Policy, Association, PTC Therapeutics, Organization, Senior, Asian Business Case Competition @ Nanyang, Review, Industry, Health equity, Therapy, Clinical trial, Program, Government, Psychology, Thought, MBA, Chair, Student, Advocacy, CEO, Solution, Committee, Patient, Drug development, Ecosystem, Public policy, Human, BMS, Bristol Myers Squibb, Thermo Fisher Scientific, Sharon Wyatt, Pharmaceutical industry, Boot camp, Insming, Medidata Solutions

TRENTON, N.J., Sept. 27, 2022 /PRNewswire/ -- BioNJ, the voice of the life sciences industry in New Jersey, announced the launch of its Health Equity in Clinical Trials Initiative .

Key Points: 
  • TRENTON, N.J., Sept. 27, 2022 /PRNewswire/ -- BioNJ, the voice of the life sciences industry in New Jersey, announced the launch of its Health Equity in Clinical Trials Initiative .
  • Committed to the vision of Health Equity for All, BioNJ's Health Equity in Clinical Trials Initiative will define concrete issues that can be remedied with impact, identify long-term interventions, support companies to improve equity and access in their clinical trials strategies, benchmark best practices and shape policy.
  • We are a proud supporter of BioNJ's Health Equity in Clinical Trials Initiative."
  • An important workstream of the Health Equity in Clinical Trials Initiative is an MBA Business Plan Case Competition.